Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01296711 · ClinicalTrials.gov registry record · Phase 2
Open-label Study to Assess the Safety and Efficacy of CDP6038 (Olokizumab) in Patients Who Completed RA0056
A Phase 2 study, sponsored by UCB Biosciences.
- Terminated
- Registry status
- Phase 2
- Development phase
- 190
- Enrollment target
NCT01296711 is a Phase 2 study that was terminated before completion, run by UCB Biosciences. The registered enrollment target is 190 participants.
The verdict
NCT01296711, a Phase 2 study, was terminated before completion, sponsored by UCB Biosciences.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 190 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the long term safety and tolerability of CDP6038 (olokizumab) treatment in adult subjects with active rheumatoid arthritis who completed study RA0056 (NCT01242488).
Interventions
- BIOLOGICAL CDP6038 (olokizumab)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 190 participants |
| Start Date | 2011-03-07 |
| Est. Completion | 2013-08-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01296711
The ClinicalTrials.gov registry entry for NCT01296711 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 190 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCB Biosciences, which has 39 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CDP6038 (olokizumab) is the first listed.
NCT01296711 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01296711 about?
NCT01296711 is a clinical study titled "Open-label Study to Assess the Safety and Efficacy of CDP6038 (Olokizumab) in Patients Who Completed RA0056". The purpose of this study is to evaluate the long term safety and tolerability of CDP6038 (olokizumab) treatment in adult subjects with active rheumatoid arthritis who completed study RA0056 (NCT01242488).
What is the current status of trial NCT01296711?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 190 participants. The study started on 2011-03-07. Estimated completion is 2013-08-05.
What interventions are being tested in trial NCT01296711?
The interventions under investigation include: CDP6038 (olokizumab) (BIOLOGICAL).
Who is sponsoring clinical trial NCT01296711?
This trial is sponsored by UCB Biosciences, which has 39 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.